{"id":"fixed-dose-plerixafor","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL5402188","moleculeType":null,"molecularWeight":"812.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Plerixafor blocks the CXCR4 chemokine receptor on hematopoietic stem cells, disrupting their interaction with stromal cell-derived factor-1 (SDF-1) in the bone marrow microenvironment. This causes stem cells to be released into the peripheral circulation where they can be harvested for autologous stem cell transplantation. The fixed-dose formulation provides a standardized dosing approach for this mobilization strategy.","oneSentence":"Plerixafor is a CXCR4 antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood for collection and transplantation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:39:38.580Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mobilization of hematopoietic stem cells to peripheral blood for collection and autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma"}]},"trialDetails":[{"nctId":"NCT07423728","phase":"NA","title":"CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-03-01","conditions":"Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization","enrollment":160},{"nctId":"NCT01160354","phase":"PHASE1, PHASE2","title":"Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-08","conditions":"Acute Myelogenous Leukemia","enrollment":22},{"nctId":"NCT00943943","phase":"PHASE1","title":"Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-10-29","conditions":"Acute Myelogenous Leukemia, Leukemia","enrollment":33},{"nctId":"NCT00694590","phase":"PHASE1","title":"Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2008-06","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)","enrollment":24},{"nctId":"NCT01236144","phase":"PHASE1, PHASE2","title":"A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.","status":"COMPLETED","sponsor":"Cardiff University","startDate":"2011-04","conditions":"Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome","enrollment":113},{"nctId":"NCT01164475","phase":"PHASE4","title":"Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2010-10","conditions":"Non-Hodgkin's Lymphoma","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mozobil","AMD3100"],"phase":"marketed","status":"active","brandName":"Fixed Dose Plerixafor","genericName":"Fixed Dose Plerixafor","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Plerixafor is a CXCR4 antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood for collection and transplantation. Used for Mobilization of hematopoietic stem cells to peripheral blood for collection and autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}